The IPO market is recovering from the slowdown experienced towards the end of 2021, with pharma companies dominating the scene in the
Arcellx readies for $140-mln IPO. Here’s all you need to know
Categories
pharmaceuticals
Johnson & Johnson (JNJ) reports Q4 2021 earnings
Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2021 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported revenue
Bristol-Myers bets on product pipeline to beat patent issues. Is BMY a buy?
The pharma sector has been on a stable growth trajectory lately, and the trend gathered momentum when the pandemic-related emergency made companies
Infographic: How Tilray (TLRY) performed in Q2 2022
Tilray (NASDAQ: TLRY) reported second-quarter 2022 financial results before the regular market hours on Monday. Total net revenue increased 20% year-over-year to
Walgreens Boots Alliance Inc. (WBA) Q1 2022 Earnings Call Transcript
Walgreens Boots Alliance Inc. (NASDAQ: WBA) Q1 2022 earnings call dated Jan. 06, 2022, Call participants: Tiffany Kanaga -- Vice President of
IPO news: Here are a few points to note as Amylyx Pharmaceuticals goes public this week
There are quite a few pharmaceutical companies lined up to make their market debut this week. Among these is Amylyx Pharmaceuticals which
Trxade Health Inc. (NASDAQ: MEDS) Q4 2021 Research Summary
Trxade Health Inc. (NASDAQ: MEDS) is a healthcare service technology platform that mainly serves the secondary pharmaceutical supply chain, offering a web-based
IPO news: What to look for when Vigil Neuroscience goes public this week
As the first week of the new year slowly unfolds, it appears the pharmaceutical industry is taking the front seat in the
IPO Alert: Key facts about CinCor Pharma’s upcoming market debut
The healthcare sector, led by pharmaceutical and biotechnology firms, has contributed significantly to the IPO boom that sent the market into overdrive
Biofrontera sees TAM of $4 Bln for lead product Ameluz: CEO Erica Monaco
Caption: iStock Biofrontera Inc. (Nasdaq: BFRI) is a biopharmaceutical company providing specialty dermatology therapies and services in the United States. Founded in
Eli Lilly and Company (LLY) Earnings: 3Q21 Key Numbers
Eli Lilly and Company (NYSE: LLY) reported revenue of $6.7 billion for the third quarter of 2021, up 18% year-over-year. Reported net
IPO Alert: Cancer drug company Nuvectis Pharma set for $30-million IPO
After months of hectic activity, the IPO market experienced a lull in the Thanksgiving week, but it is still headed for a
Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing
Biofrontera Inc (BFRI) Q3 2021 Earnings Call Transcript
Biofrontera Inc (NASDAQ: BFRI) Q3 2021 earnings call dated Nov. 30, 2021 Corporate Participants: Pamela Keck -- Head of Investor Relations Hermann Luebbert
BMY Earnings: Key quarterly highlights from Bristol-Myers Squibb Q3 financial results
Bristol-Myers Squibb Company (NYSE: BMY) reported second-quarter 2021 earnings. Revenues increased 10% year-over-year to $11.6 billion. Net earnings attributable to Bristol Myers
Vertex Pharma (VRTX) expands cystic fibrosis pipeline; raises FY21 outlook
Biotechnology company Vertex Pharmaceuticals (NASDAQ: VRTX) has reported higher earnings and revenues for the third quarter of 2021. The bottom line also
Pfizer (PFE) stock research summary | Q3 2021
Pfizer delivered a solid performance in Q3 2021 with a triple-digit increase in revenue and profits growing many-fold. The company’s COVID-19 vaccine,
ACB Earnings: Aurora Cannabis Q1 2022 revenue down 11%
Aurora Cannabis, Inc. (NYSE: ACB) on Tuesday reported a loss for the first quarter of 2022 when its revenues declined 11% from
IPO news: A few points to keep in mind as Vaxxinity makes its market debut this week
The healthcare industry continues to thrive and many companies in this sector have lined up to go public in recent times. One
Pfizer (PFE): Comirnaty and a strong pipeline provides long-term growth opportunity
Shares of Pfizer Inc. (NYSE: PFE) gained 4% on Tuesday after the company delivered strong results for the third quarter of 2021
Key highlights from Pfizer (PFE) Q3 2021 earnings results
Pfizer Inc. (NYSE: PFE) reported third quarter 2021 earnings results today. Revenues more than doubled year-over-year to $24 billion. Reported net income